Literature DB >> 24941289

Regulation of myelopoiesis by CD137L signaling.

Qianqiao Tang1, Dongsheng Jiang, Zulkarnain Harfuddin, Kin Cheng, Mei Chung Moh, Herbert Schwarz.   

Abstract

CD137 ligand (CD137L) has emerged as a powerful regulator of myelopoiesis that links emergency situations, such as infections, to the generation of additional myeloid cells, and to their activation and maturation. CD137L is expressed on the cell surface of hematopoietic stem and progenitor cells (HSPC) and antigen presenting cells (APC) as a transmembrane protein. The signaling of CD137L into HSPC induces their proliferation and differentiation to monocytes and macrophages, and in monocytes CD137L signaling induces differentiation to potent dendritic cells (DC). CD137L signaling is initiated by CD137 which is expressed by T cells, once they become activated. Some of these activated, CD137-expressing T cells migrate from the site of infection to the bone marrow where they interact with HSPC to induce myelopoiesis, or they induce monocyte to DC differentiation locally at the site of infection. Therapeutically, induction of CD137L signaling can be utilized to reinitiate myeloid differentiation in acute myeloid leukemia cells, and to generate potent DC for immunotherapy.

Entities:  

Keywords:  CD137; T cells; infection; myelopoiesis

Mesh:

Substances:

Year:  2014        PMID: 24941289     DOI: 10.3109/08830185.2014.921163

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  5 in total

1.  Loss of intraepidermal nerve fiber density during SIV peripheral neuropathy is mediated by monocyte activation and elevated monocyte chemotactic proteins.

Authors:  Jessica R Lakritz; Jake A Robinson; Michael J Polydefkis; Andrew D Miller; Tricia H Burdo
Journal:  J Neuroinflammation       Date:  2015-12-18       Impact factor: 8.322

Review 2.  Tumor progression mechanisms: Insights from the central immune regulation of tissue homeostasis.

Authors:  Natalya Lisovska; Nasrulla Shanazarov
Journal:  Oncol Lett       Date:  2019-04-05       Impact factor: 2.967

3.  Deletion of CD137 Ligand Exacerbates Renal and Cutaneous but Alleviates Cerebral Manifestations in Lupus.

Authors:  Anselm Mak; Bhushan Dharmadhikari; Nien Yee Kow; Thomas Paulraj Thamboo; Qianqiao Tang; Lik Wei Wong; Sreedharan Sajikumar; Hiu Yi Wong; Herbert Schwarz
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

Review 4.  Multilevel mechanism of immune checkpoint inhibitor action in solid tumors: History, present issues and future development.

Authors:  Natalya Lisovska
Journal:  Oncol Lett       Date:  2022-04-29       Impact factor: 3.111

5.  Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial.

Authors:  C Sköld; K Kultima; E Freyhult; A Larsson; T Gordh; N P Hailer; H Mallmin
Journal:  Osteoporos Int       Date:  2022-05-24       Impact factor: 5.071

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.